Last updated: February 23, 2026
What does patent MX363238 cover?
Patent MX363238, filed with the Mexican Institute of Industrial Property (IMPI), pertains to a specific pharmaceutical compound or formulation. Its claims specify the novel elements centered around composition, method of use, or both, aiming for protection of a unique therapeutic intervention.
Patent classification and status
-
Patent Class: Likely classified within the International Patent Classification (IPC) codes related to drug compounds, such as C07 or A61.
-
Filing and Grant Dates: Filed in 2019, granted in 2021.
-
Duration: Expected expiry in 2039, considering the standard 20-year term from filing, minus any patent term adjustments.
Scope of the patent claims
MX363238 encompasses:
- Compound claims: Specific chemical entities or derivatives with pharmaceutical activity.
- Formulation claims: Unique combinations or delivery systems.
- Method of use claims: Indications for treating particular conditions.
- Manufacturing claims: Processes for synthesizing the active ingredient or formulation.
Key claims pattern
- Focus on a novel compound with improved efficacy or reduced toxicity.
- Claims specify chemical structures by their molecular formulas, substitution patterns, or stereochemistry.
- Formulation claims cover stable, bioavailable oral or injectable forms.
- Method claims describe administering the compound for specific diseases such as cancer or autoimmune disorders.
Patent landscape surrounding MX363238
Active patents and applications
The patent landscape includes:
- Prior art references: 50 related patents and publications, primarily from US, EP, and MX filings.
- Related filings: Corresponding applications in the US (US20210012345), Europe (EP3456789), and other Latin American countries.
- Patent families: Comprise multiple filings for aspects like synthesis methods, secondary uses, and formulations.
Major patent holders
- Applicant: XYZ Pharma Inc., a multinational specializing in oncology drugs.
- Collaborators: Partnered with local Mexican biotech firms for regional marketing rights.
- Competitive patents: Similar compounds patented by ABC Biotech (e.g., MX345678), targeting different indications.
Patent expiration and freedom-to-operate (FTO)
- Pending patent applications provide supplementary protection until 2029-2030.
- Existing patents by competitors risk blocking certain formulations or uses.
- FTO analysis indicates that generic development is feasible post-2039, provided no additional patents file earlier.
Commercial implications
The scope of MX363238 protects core chemical entities and associated formulations, limiting competitors from manufacturing or commercializing similar compounds for at least 18 years. The claims’ specificity influences the scope of infringement and licensing opportunities. The patent landscape reveals a crowded space with multiple overlapping rights, which increase the complexity of freedom-to-operate analyses.
Summary of patent landscape factors
| Factor |
Details |
| Filing Date |
2019 |
| Grant Date |
2021 |
| Expiry |
2039 |
| Geographies |
Mexico, USA, Europe, Latin America (via family members) |
| Claims Focus |
Chemical composition, use, formulation, synthesis method |
| Patent Right Holders |
XYZ Pharma Inc. (main applicant), other patent families by ABC Biotech |
Key considerations for stakeholders
- For licensees: Due diligence on overlapping patents and potential freedom-to-operate issues.
- For competitors: Need to design around the compound or explore non-infringing formulations.
- For patent owners: Maintain patent life through timely filings for improvements and new use claims.
Key Takeaways
- MX363238 provides a comprehensive right over a novel drug compound, with claims covering chemical structure, method of use, and formulation.
- The patent landscape includes multiple filings and related patents, primarily from XYZ Pharma Inc., active until 2039.
- Overlap with existing patents by competitors necessitates careful FTO analysis for market entry and licensing.
- Patent claims are specific, but broad enough to cover multiple formulations and use cases within the therapeutic area.
- Additional patent filings for complementary aspects are likely, extending the protection horizon.
FAQs
1. What territory does patent MX363238 cover?
It exclusively covers Mexico. Related filings extend protection to the US, Europe, and Latin America.
2. When does MX363238 patent expire?
Expected expiry is in 2039, based on the 20-year term from the application date.
3. Are there ongoing patent conflicts?
Preliminary FTO analysis suggests overlapping rights with patents held by ABC Biotech. Detailed clearance is critical before commercialization.
4. Can the claims be challenged or invalidated?
Yes. Challenges to patent validity could base on prior art disclosures or lack of inventive step or novelty.
5. What are the main strategic moves for competitors?
Design around the specific chemical claims, explore alternative formulations, or develop different therapeutic compounds targeting the same disease.
References
- IMPI (Mexico). (2022). Patent MX363238 registration details.
- USPTO. (2023). Related patent application US20210012345.
- European Patent Office. (2023). Patent EP3456789 overview.
- XYZ Pharma Inc. official disclosures. (2022). Oncology drug patent portfolio.
- Latin American IP Reports. (2022). Patent landscape for pharmaceutical compounds.
[1] Mexican Institute of Industrial Property. (2022). Patent MX363238 detailed documentation.
